These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 35951740)
1. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. Lee JS; Kim CY Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740 [TBL] [Abstract][Full Text] [Related]
2. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial. McLaurin E; Cavet ME; Gomes PJ; Ciolino JB Optom Vis Sci; 2018 Mar; 95(3):264-271. PubMed ID: 29461408 [TBL] [Abstract][Full Text] [Related]
3. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness. Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262 [TBL] [Abstract][Full Text] [Related]
5. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops. Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653 [TBL] [Abstract][Full Text] [Related]
6. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
7. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Schuman JS Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247 [TBL] [Abstract][Full Text] [Related]
9. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154 [TBL] [Abstract][Full Text] [Related]
10. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman JS Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839 [TBL] [Abstract][Full Text] [Related]
11. Over-the-Counter Ocular Decongestants in the United States - Mechanisms of Action and Clinical Utility for Management of Ocular Redness. Hosten LO; Snyder C Clin Optom (Auckl); 2020; 12():95-105. PubMed ID: 32801982 [TBL] [Abstract][Full Text] [Related]
12. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters TR Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246 [TBL] [Abstract][Full Text] [Related]
13. OTC brimonidine (Lumify) for ocular redness. Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046 [No Abstract] [Full Text] [Related]
14. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823 [TBL] [Abstract][Full Text] [Related]
15. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181 [TBL] [Abstract][Full Text] [Related]
17. The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery. Ucar F; Cetinkaya S J Ocul Pharmacol Ther; 2021 May; 37(4):230-235. PubMed ID: 33684337 [No Abstract] [Full Text] [Related]
18. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Cantor LB Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518 [TBL] [Abstract][Full Text] [Related]
19. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. Okwundu N; Cline A; Feldman SR J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643 [TBL] [Abstract][Full Text] [Related]